
USD
+$0.00
(+0.00%
)At Close (As of Dec 10, 2025)
$25.80B
Market Cap
16.03
P/E Ratio
10.97
EPS
$185.17
52 Week High
$110.04
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $7.4B |
| Total Revenue | $9.7B |
| Cost Of Revenue | $2.3B |
| Costof Goods And Services Sold | $2.3B |
| Operating Income | $2.5B |
| Selling General And Administrative | $2.3B |
| Research And Development | $2.5B |
| Operating Expenses | $4.9B |
| Investment Income Net | - |
| Net Interest Income | -$183M |
| Interest Income | $68M |
| Interest Expense | $250M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $673M |
| Income Before Tax | $1.9B |
| Income Tax Expense | $274M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.6B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.3B |
| Ebitda | $3B |
| Net Income | $1.6B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $2.9B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $673M |
| Capital Expenditures | $360M |
| Change In Receivables | - |
| Change In Inventory | -$274M |
| Profit Loss | - |
| Cashflow From Investment | -$799M |
| Cashflow From Financing | -$684M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $1.6B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $7.4B |
| Total Revenue | $9.7B |
| Cost Of Revenue | $2.3B |
| Costof Goods And Services Sold | $2.3B |
| Operating Income | $2.5B |
| Selling General And Administrative | $2.3B |
| Research And Development | $2.5B |
| Operating Expenses | $4.9B |
| Investment Income Net | - |
| Net Interest Income | -$183M |
| Interest Income | $68M |
| Interest Expense | $250M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $673M |
| Income Before Tax | $1.9B |
| Income Tax Expense | $274M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $1.6B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $2.3B |
| Ebitda | $3B |
| Net Income | $1.6B |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Biogen Inc. is a leading biotechnology firm based in Cambridge, Massachusetts, renowned for its pioneering work in the discovery and development of innovative therapies for neurological disorders. The company boasts a comprehensive pipeline that addresses critical conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, positioning itself as a key player in meeting substantial unmet medical needs. Committed to advancing therapeutic innovation, Biogen leverages strategic partnerships and a deep commitment to scientific research, reinforcing its status as a prominent leader within the biotechnology industry and its dedication to improving patient outcomes.